Valuation
NRIXNurix Therapeutics Inc
StockNasdaqStany ZjednoczoneHealth careEU retail: available
2/10
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | NRIX | Sector median | vs median |
|---|---|---|---|
| P/E | 8,8 | 28,8 · n=114 | 70% below |
| P/B | 2,7 | 3,0 · n=196 | 11% below |
| P/S | 3,7 | 3,7 · n=202 | near the median |
| EV/EBIT | 6,4 | 24,1 · n=103 | 73% below |
| Free-cash-flow yield | 14,3% | 2,8% · n=187 | 410% above |
| Dividend yield | 0,00% | 0,00% · n=215 | — |
| Return on equity | 44,0% | 2,7% · n=193 | 1 555% above |
| Return on invested capital | 106,9% | 3,5% · n=176 | 2 913% above |
| Gross margin | — | 62,5% · n=152 | — |
| Net debt / EBITDA | −2,41 | 1,19 · n=108 | 302% below |
Value factor: 92 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| LLYEli Lilly & Co | 42,6 | 33,6 | — | 1,6% | 0,6% | 6/10 |
| JNJJohnson & Johnson | 29,1 | 7,2 | — | 3,6% | 2,1% | 8/10 |
| ABBVAbbVie | 79,9 | — | 33,5 | 3,6% | 3,0% | 5/10 |
| MRKMerck | 114,6 | 8,7 | — | 4,4% | 2,3% | 8/10 |
| UNHUnitedHealth | 25,1 | 3,4 | 18,6 | 6,7% | 2,3% | 9/10 |
| TMOThermo Fisher Scientific | 35,7 | 4,7 | 35,2 | 2,9% | 0,3% | 8/10 |
| AMGNAmgen | 26,3 | 19,7 | 24,0 | 4,4% | 2,3% | 6/10 |
| GILDGILEAD | — | 16,1 | — | 6,8% | 2,1% | 4/10 |
| ABTAbbott | 28,5 | 3,4 | 26,8 | 4,1% | 3,0% | 5/10 |
| PFEPfizer | 38,4 | 2,0 | — | 6,6% | 5,9% | 1/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 sie 2026 · filed 13 paź 2026
WYCOFAJ SIĘ Z KONTRAKTU TUTAJ · Klienci z UE: 14 dni na odstąpienie od umowy.